Day 3, Thursday, March 20th, 2025 - EST/EDT (Eastern Daylight, GMT-4)
- Patrick Gomez Menzies - Head of Market Access, AIR, US, Chiesi USA, Inc.
This case study explores EMD Serono’s approach to cultivating a strong company culture and its direct impact on team engagement, retention and productivity. The study defines what company culture is and how it shapes daily operations and employee behavior. It highlights the critical role of leadership in fostering and maintaining a positive work environment and demonstrates how a well-established culture drives employee engagement. The case study also examines how a thriving culture contributes to long-term employee retention and increased productivity, providing actionable strategies for organizations aiming to enhance their internal dynamics.
- Amanda Bellitti - Director, Patient Access Care & Engagement Programs, EMD Serono
- Dolores Garcia-Hoffman - Associate Director, N&I Program Management of Patient Access Solutions, EMD Serono
As PBMs continue deploying accumulators, maximizers and alternative funding programs to drive cost savings, the ripple effects on patients, manufacturers, and healthcare ecosystems are undeniable. This session delivers critical updates on these strategies and offers actionable insights to help your organization stay ahead.
- Identify strategies and unique hub solutions so manufacturers can continue to prioritize patient access and affordability
- Understand the current state of employer perspectives and the impact on patients
- Stay informed on evolving state and federal regulatory developments affecting these programs
- Meredith McDonald - Director, Patient Access, Exelixis Inc
- Vicki Karlan - US Market Access Strategy Lead, Pfizer
- Kimberly Westrich - Chief Strategy Officer, National Pharmaceutical Council
Overview copay smoothing to understand what it is, how it differs from traditional Part D benefit structure and its overall mechanics.
Highlight the advantages of copay smoothing for patients whilst also discussing the challenges and opportunities for health plans and other stakeholder groups.
Discuss the importance of effective communication and education during open enrollment to ensure that patients are informed about copay smoothing options.
- Vicki Karlan - US Market Access Strategy Lead, Pfizer
- Richard Fahrer - Director, Oncology Patient Solutions & Alliances, Pfizer
Causal AI is an exciting technology that can enable next-best-action precision and organizational adaptability to support adherence and persistence at the individual patient level. This session will delve into the theory and practice behind Causal AI’s promise, including:
- The differentiating features of Causal AI from other technological advancements and the power of unlocking cause-and-effect relationships behind early patient discontinuation of specialty medications
- How counterfactual analyses can be used to tailor interventions to unique patient needs
- How Causal AI supports transparency and trust across stakeholders supporting the patient journey
- The diversity of datasets and information sources that Causal AI can leverage
- Ashutosh Katiyar - Executive Director, Commercial Strategy, Insights and Analytics, Regeneron
- Nicole Pay - Head of Analytics, Vaalia Health
- Jacob Jolly - Head of Pharmacy, Vaalia Health
Digital health is transforming the way patients and providers interact, offering new opportunities to improve engagement, streamline care, and enhance satisfaction. This session will explore the evolving role of digital health from, pharma, patient and provider perspectives. We will discuss real-world applications of digital tools used in clinics and pharma, as well as the technologies patients are adopting to manage their health. Topics will include remote patient monitoring, AI-driven tools, patient portals, and telehealth solutions. By examining these innovations, we will highlight how digital health fosters better communication, supports shared decision-making, and ultimately leads to improved health outcomes. Join us for an interactive discussion on the future of digital health and how to optimize its impact.
- Jin Lee - Investor, Oxford Angel Fund
- Shamekka Marty - Ambassador, National Minority Health Association
- Cheryl Roche Alexander, DNP, EMBA - Founder, Enlightened Consulting
With the election behind us and a new administration in place, the impact on healthcare legislation and regulatory priorities is coming into focus. This session examines key policy shifts, congressional dynamics and the evolving relationship between government and the (health) life sciences sector.
- Assess how the new administration’s priorities and congressional leadership changes are shaping healthcare policies, including drug pricing, market access, and patient assistance programs.
- Examine the possible implications for industry
- Gain strategic insights into navigating the evolving political landscape, engaging effectively with policymakers
- Max Bronstein - President, MGB Consulting
- Rachel Nuzum - Senior Vice President, Policy, The Commonwealth Fund
- Chris Kelly - Vice President, BGR Group
- Shanelle Gabriel - Lupus Patient Advocate & Artist, Starting Something Productions, Inc